Why has gastric cancer been decreasing in Western societies during the past decades? The answer is largely unknown, but it may be related to a worldwide decrease in the prevalence of H. pylori infections. However, in addition to H. pylori, there are several host-related and environmental factors that contribute to the etiopathogenesis of gastric carcinoma. The exact mechanism(s) how H. pylori and genetic and molecular abnormalities exert their carcinogenic actions in the stomach are addressed in detail by Pelayo Correa (Nashville, TN) and Wataru Yasui (Hiroshima) with their coworkers in expertly composed articles in this issue of the Journal.
Surgery is the only cure for gastric cancer. In Western societies the way surgery is performed to cure gastric cancer has remained basically unchanged since the times of Karl Schlatter who performed the first total gastrectomy in Zürich in 1897. Not surprisingly, then, only modest progress in the results of surgical treatment of gastric cancer has been witnessed in the Western countries during the past decades. Also in Japan, limited gastrectomy (D1) -similar to what was done in the Western countries -was used in the early 20 th century to treat gastric cancer, and the results were likewise poor. But then, in the 1960's after careful mapping of the lymph drainage of stomach, Japanese surgeons developed a more radical type of gastrectomy which included extended lymphadenectomy (D2). This procedure became popular and was widely adopted by Japanese surgeons in late 1960's. This led, with time, to dramatic improvement in the results of gastric cancer surgery in Japan. Better and earlier diagnosis of gastric cancer doubtlessly contributed to this improvement, but the superiority of Japanese surgery emerged nevertheless also when survival figures were adjusted for the patients' disease stage. Since then surgery, as well as other treatment modalities, have been further refined, and in the late 1900's Japan and some Far East countries became and have remained global spearheads in the field of gastric cancer research and clinical management. In this issue Mitsuro Sasako and his colleagues (Tokyo) describe modern gastric cancer surgery in Japan.
Although experienced Western centers have also reported D2 gastrectomies with results comparable to the Japanese results, the debate about the benefits of D1 vs D2 lymphadenectomies continues. A definitive resolution of this debate would require a randomised trial by Japanese surgeons well acquainted with both techniques of lymph node dissection. However, convinced of the superiority of D2 dissection, Japanese surgeons have been reluctant to conduct such a trial. Instead, there are two large European randomised trials comparing D1 and D2 dissections, the Dutch D1-D2 trial and the British Medical Research Council Trial. Both trials failed to show a survival benefit in the favour of D2 dissection; morbidity and mortality were significantly higher in the D2 dissection arms in both trials. The Dutch D1-D2 trial was planned very carefully -special attention was paid on surgical quality assurance, e.g. by recruiting a Japanese surgeon to instruct and to supervise D2 surgery. Yet, the trial has been criticised because it was spread over a large number of hospitals, giving, naturally, a very low load of D2 patients per hospital. There was also a great number of protocol violations in terms of lymph node dissection (contamination and non-compliance). The characteristics of this trial are described in detail in this issue by Cornelis van de Velde and his group (Leiden).
The discrepancy between the European and Japanese results regarding D1-D2 lymph node dissection might be explained through Maruyama index analysis, at least as regards the Dutch D1-D2 trial. As discussed by Scott Hundahl (Mather, CA), the survival of gastric cancer patients after surgery may also be dependent on the Maruyama index of the operation, i.e. how meticulously the metastasis-bearing lymph nodes are surgically removed. When Maruyama index analysis was applied to the Dutch D1-D2 trial it turned out that patients who had undergone meticulous lymph node dissection and had a low Maruyama index (< 5) had significantly better overall survival and disease-free survival than patients with incomplete lymph node dissection and a high Maruyama index (> 5).The analysis showed also that there was a strong "dose response" effect for the Maruyama index with regard to survival.
Early gastric cancer is defined as adenocarcinoma of stomach limited to the mucosa or submucosa, regardless size and metastatic status. In the Eastern hemisphere up to 70% of all gastric cancers are diagnosed (and treated) as early gastric cancers, but the rate in the Western hemisphere is only 15-20%. Obviously, this is not a real difference in incidence -the huge difference between these figures must be due to inadequate early diagnosis of gastric cancer in Western countries. This is also reflected in the consensus of the Occident that early gastric cancer is only a transient stage in the natural history of gastric malignancy which ultimately develops into an invasive cancer unless treated in time. In a paper by Takeshi Sano (Tokyo) and Andrew Hollowood (Bristol) early gastric cancer, including its treatment, is discussed at expertly depth. They point out that since early gastric cancer is non-invasive and small in size, it can be treated by a much more conservative approach than invasive cancers. Indeed, even local therapeutic measures, e.g., endoscopic mucosal resection or endoscopic submucosal dissection, may be sufficient treatment, provided that certain prerequisites are met. These timely treatments seem to save patients completely from an untimely death.
One crucial prerequisite for local treatment is that there must be no lymph node metastases, something that is difficult, if not impossible, to ascertain with current diagnostics. Here, maybe sentinel node navigation could be the key to solve this important issue, as discussed by Yoko Kitagawa and colleagues (Tokyo). The sentinel node is the first lymph node in the field of lymph nodes that drain the area of the primary lesion (and flushes metastatic cells as lymph is drained). The hypothesis, yet unproven, is that if the sentinel node is free of metastases, there are no metastases in this regional lymph drainage field, and the disease (here, early gastric cancer) is amenable to local treatment. In certain solid tumours, such as melanoma and breast cancer, the sentinel node has proven to be a good indicator of the metastatic status of regional lymph nodes, and the method is in clinical use. The outcome of using sentinel node biopsy when these diseases are treated seems to be that the overall need for invasive surgical treatments has declined. In gastric carcinoma, however, the debate is still heating and the issue is unresolved.
Unlike the non-cardia gastric carcinomas, which are decreasing in number, the carcinomas of the esophagogastric region, or the cardia, are strongly increasing in the West. These cancers, usually named "cardia carcinomas" in the past, are a heterogenous group of tumors with different etiopathogenesis, histopathology, oncological behaviour, epidemiology and treatment. This, well, mess has long confused surgeons and investigators. For example, H. pylori infection plays an important role in the etiology of the cardia carcinomas at the gastric side of esophago-gastric junction, but no role in cardia cancers at the esophageal side of the junction, where, on the other hand, gastro-esophageal reflux seems to be important. J. Rüdiger Siewert and his group (Munich) have created a new classification of the tumors of the esophago-gastric junction, which has been widely accepted and is widely used. Siewert's classification has standardized our diagnostic-therapeutic approach to these tumors and facilitated our communication about them. One of the fruits of this classification is that we are now comparing Barrett's carcinoma with Barrett's carcinoma and subcardial gastric carcinoma with subcardial gastric carcinoma when scrutinising our surgical results.
A new mode of adjuvant therapy for gastric cancer, based on intraperitoneal chemotherapy, has been introduced by Paul Sugarbaker and coworkers (Washington, DC). Resection site recurrence and peritoneal carcinomatosis occur often in patients in whom the primary gastric cancer resection has failed. The rationale of instilling chemotherapeutic agents directly into the peritoneal cavity immediately after what is thought to have been curative gastric cancer resection is to expose the peritoneal surfaces to a high local concentration of the chemotherapeutic agents for a prolonged time at minimal systemic toxicity. Later during the trial, the intraperitoneal chemotherapeutic perfusate was heated in an effort to increase efficacy. As reviewed by Paul H. Sugarbaker, this type of adjuvant therapy seems to be of considerable benefit to patients with gastric cancer, especially if they have tumours with serosal involvement.
